Announcement PDF ImpediMed Limited Suite 31C, 12-18 Tryon Rd Lindfield NSW 2070 Australia E: investorrelations@impedimed.com W : impedimed.com 27 August 2026 Companies Announcements Office Australian Securities Exchange 2026 Annual Report ImpediMed Limited (ASX:IPD) is pleased to release its Annual Report for the financial year ended 30 June 2026. Approved for release by the Board of ImpediMed Limited. For more information, contact Leanne Ralph, Company Secretary, at leanne.ralph@bellev.com.au Transforming Connected, Personalised Care impedimed.com Overview Contents ImpediMed is a leading global medical technology company that manufactures and sells innovative medical devices employing bioimpedance spectroscopy (BIS) technology. These devices are used for the non-invasive clinical assessment and monitoring of fluid status and tissue composition in patients. ImpediMed is primarily addressing the significant challenges and burdens of secondary lymphoedema, with a particular focus on breast cancer-related lymphoedema (BCRL). Through the SOZO® Digital Health Platform and L-Dex® , ImpediMed offers the only FDA-cleared technology utilising bioimpedance spectroscopy (BIS), and remains the standard of care for the early detection and management of BCRL. Broadening this reach across cancer survivorship, BodyComp™ Analysis is gaining momentum in supporting interventions such as exercise oncology, lifestyle medicine, and wellness programs. Building on this foundation, ImpediMed is extending the same platform and clinical rigour into two additional growth markets: heart health, where the SOZO platform is the only FDA-cleared BIS solution for assessing fluid status in heart failure patients, and medical weight management, where growing GLP-1 adoption is driving demand for body composition monitoring beyond the scale. One system, one cloud platform, and one continuous patient record now support all three. Our commitment is to address significant unmet patient needs across cancer survivorship, cardiac care, and weight management, improving long-term health outcomes through innovation in the design and delivery of fluid and body composition analytics. Our Board and Executive Leadership team are leading a refined strategy focused on sales execution, disciplined commercial expansion, and customer-centric innovation. Our mission: To improve patient outcomes by setting new standards of care in fluid and body composition management. Overview Message from the Chair Message from the CEO SOZO® Digital Health Platform Operating and financial review Environmental, Social and Governance Board of Directors Executives Directors’ report Remuneration report Auditor's independence declaration Financial statements Consolidated entity disclosure statement Directors' declaration Independent auditor's report Shareholder information Glossary Corporate directory 01 02 03 05 10 14 16 17 19 25 40 41 82 83 84 89 92 93 01 On behalf of the Board of Directors and Management, I am pleased to present the Annual Report for ImpediMed Limited for the 2026 financial year. Thank you to our shareholders for your continued support. FY26 delivered continued progress against the strategy set in 2024, with revenue up 15% (or 20% in constant currency) and reimbursement coverage for breast cancer-related lymphoedema reaching 95% of the U.S. population. Further detail on these results is provided in the review of operations. From the Board's perspective, what stands out is the disciplined approach the team is taking to convert a large addressable market into durable, recurring revenue growth. FY26 also saw ImpediMed extend beyond its core lymphoedema business, launching SOZO® Pro commercially into Heart Health and Weight Management. Both are large, underserved markets where our existing clinical, regulatory and commercial footprint gives us a genuine advantage, and both are still in the early, disciplined stages of their build-out. On behalf of the Board, I want to acknowledge Dr Parmjot Bains, who stepped down as Managing Director and CEO during the year after leading the Company through a period of significant transformation since January 2024. Parmjot's focus on sales execution, reimbursement expansion and clinical validation materially strengthened the business she has handed on, and the Board thanks her for her contribution. In April 2026, we welcomed Erik Anderson as Managing Director and CEO. Erik brings twenty years of US commercial healthcare leadership, most recently as Division President of Hologic's Breast and Skeletal Health business, and the Board is confident in his ability to build on the foundation laid to date while sharpening our commercial execution and financial discipline. Extending the SOZO Platform, appointment of new leadership and financial discipline have been defining themes of the year. In June 2026, the Company completed a $15.3 million equity raising, used in part to partially repay our debt facility underpinned with $5.0 million in annualised operating cost reductions. Together with continued revenue growth, these actions put ImpediMed on a clearer path to operating cash flow breakeven. I would like to acknowledge my fellow directors, whose guidance through a year of both growth and change has been invaluable, and to thank our ImpediMed employees, whose commitment to patients continues to drive the Company forward. On behalf of the Board, thank you for your continued support as we build the next chapter of ImpediMed's growth. Christine Emmanuel-Donnelly Chair Sincerely Message from the Chair Christine Emmanuel-Donnelly Chair of the Board 02 FY26 was a year of real progress, and there is more work ahead of us to fully capture the opportunity in front of this business. Revenue grew, reimbursement expanded significantly, and our platform offering got stronger. Our commercial execution is strengthening to match the size of this opportunity, and that is the work we are focused on now. Our foundation in Breast Cancer-Related Lymphoedema surveillance is strong, and it is the proof point for something bigger. The clinical case for SOZO is proven. The reimbursement is in place. What we are now doing is expanding how we engage health systems at an enterprise level to capture the full value of that position. The focus on cancer survivorship has never been greater. Patients today are living longer after surgery, radiation, chemotherapy, and hormone therapy, and each of those treatments carries its own lasting impact on the body that needs to be tracked and managed over time to reduce the risk of cancer recurrence and keep patients healthy. At the same time, the rise of GLP-1 use across the broader population is bringing new attention to lean muscle mass and body composition as a marker of long-term health, including for cancer survivors. Exercise oncology is also emerging as a critical pillar of survivorship care, with a growing body of clinical evidence showing that objective, measurable data is what allows care teams to prescribe and monitor exercise as a therapeutic intervention, not just a lifestyle recommendation. We are also seeing survivorship guidelines and accreditation standards continue to evolve in ways that call for exactly the kind of objective, longitudinal measurement the SOZO Platform was built to provide. This is a moment where the tools available to support survivors need to catch up with how much medicine has advanced. We believe the SOZO Platform is positioned to be a foundational part of that answer, and we are expanding our commercial reach to the stakeholders who build and fund these programs: the Survivorship Director, the VP of Oncology Operations, the Nurse Navigator, the Quality leader, alongside the surgeon who remains central to everything we do in breast cancer. This is how we take a proven clinical win in one department and turn it into an enterprise-wide platform across the health system. The numbers Total revenue reached $14.6 million, up 15% (or 20% in constant currency) year on year. Reimbursement coverage for breast cancer-related lymphoedema reached 95% of the U.S. population, up from 82%. Our installed base grew to 1,236 systems globally. More than 1.5 million patient tests have now been completed since launch, 324,000 of them this year alone. SOZO Pro extended the platform into Heart Health and Weight Management, both now in early commercial build-out. SOZO Pro remains the only FDA-cleared bioimpedance device available to patients with cardiac implantable devices, and it now carries a Medicare National Coverage Determination covering roughly 75% of heart failure patients. Weight Management is early, but the GLP-1 tailwind is real and growing, touching every patient population across cancer survivorship, cardiac care, obesity medicine, and wellness segments. We strengthened the balance sheet with a $15.3 million capital raise, paid down $5.0 million in debt, and cut $5.0 million in annualised costs. We also brought in the commercial leadership this business needed to build real pipeline discipline and account depth. Message from the CEO Erik Anderson Managing Director and CEO 03 People, Performance, Culture None of this works without the right people in the right roles. Since joining, I have focused on building an organisation defined by clear goal alignment, role clarity, and high accountability. We are operating with urgency, because the patients and caregivers who stand to benefit from the SOZO Platform deserve nothing less. Looking ahead In FY27, our priorities are clear: 1. Deepen Lymphoedema+ and the wider survivorship platform across existing and new health system accounts; 2. Drive greater utilisation and growth within our current customer base; 3. Scale Heart Health and Weight Management with a disciplined, results-focused approach and continue toward cash flow breakeven. I want to thank Dr Parmjot Bains for her leadership and the foundational work built over the last several years. I want to thank our employees for their passion and focus, and our shareholders for their continued support as we look to significantly strengthen this business every day. Erik Anderson Managing Director and CEO Message from the CEO 04 One Platform. Three Growing Markets. SOZO Digital Health Platform Growth (as of 30 June 2026) One platform. Multiple FDA-cleared applications. Proven outcomes. ImpediMed's SOZO® Digital Health Platform is redefining how clinicians monitor fluid status and tissue composition — from a single 30-second, non-invasive scan. Built on proprietary bioimpedance spectroscopy (BIS) technology that sends 256 unique frequencies through the body, SOZO gives care teams objective, longitudinal data they can act on immediately and trend over time through cloud-based, HITRUST-certified software. FY26 marked a pivotal step in extending that platform beyond its foundation in breast cancer-related lymphoedema (BCRL) detection. Today, the SOZO Digital Health Platform supports three converging growth markets — cancer survivorship, heart health, and medical weight management — unified by one system, one cloud platform, delivering one continuous patient record. Leading that expansion is SOZO® Pro, our latest-generation system, which adds integrated weight measurement to deliver comprehensive fluid status and tissue composition data in a single streamlined assessment. 05 A single SOZO measurement provides: L-Dex® lymphoedema analysis HF-Dex® heart failure analysis BodyCompTM analysis Hy-Dex® hydration analysis Lymphoedema - FDA clearance, CE Mark Body composition - FDA clearance, CE Mark Heart failure - FDA clearance, CE Mark Protein calorie malnutrition - FDA clearance, CE Mark One solution, multiple regulatory authority cleared applications 1,236 SOZO systems placed globally, incl. 642 in the U.S. 331M Covered lives — 95% U.S. national reimbursement coverage for L-Dex 1.5M Patient tests: 16% 3-year CAGR in patient testing volume (FY23–FY26) 18/25 Of the top 25 U.S. hospitals are SOZO customers Source: ImpediMed Q4 FY26 Quarterly Activities Report and Investor Presentation (ASX: IPD), released 28 July 2026 1 1. US News Best Hospitals for Cancer rankings https://health.usnews.com/best-hospitals/rankings/cancer For many of the 18 million cancer survivors in the United States — a population growing by more than one million people each year — completing treatment for their cancer does not mark the end of the health journey. Up to 1 in 5 breast cancer patients will go on to develop secondary lymphoedema, a painful, chronic condition that can dramatically impact quality of life, while up to 60% of survivors report an ongoing fear of cancer recurrence. Many also face muscle wasting and fatigue, with limited tools available to detect these changes early. The SOZO Digital Health Platform remains the only FDA-cleared, CE-marked and ARTG-listed BIS solution for lymphoedema assessment, and clinical guidelines continue to reinforce its role: in May 2025, the NCCN Clinical Practice Guidelines in Oncology reaffirmed BIS as the recommended tool for pre-treatment baseline measurement and ongoing screening in at-risk cancer patients, joining standing recommendations from the American Society of Breast Surgeons, International Society of Lymphology, Oncology Nursing Society, Multinational Association of Supportive Care in Cancer, and the American Physical Therapy Association. NAPBC accreditation standards for survivorship continue to recommend use of evidence-based guidelines to implement protocols for survivorship, which can include a lymphoedema prevention program for regular symptom assessment and clinical evaluation using BIS. In FY26, ImpediMed sharpened this opportunity into a formal commercial strategy — Lymphoedema + Body Composition — that leads with SOZO® Pro to support a multidisciplinary view of survivorship. From a single streamlined assessment, SOZO Pro captures L-Dex® lymphoedema analysis, BodyComp™ body composition analysis, and integrated weight in under 30 seconds, giving oncology, physical therapy, and wellness teams one consistent longitudinal record for each patient rather than three disconnected measurements. BodyComp™ analysis is FDA-cleared for unhealthy populations, delivering patient data that clinicians can trust. Lymphoedema + Body Composition: A Broader Standard of Survivorship Care Leading with Lymphoedema + Body Composition Monitoring 06 Source: NCCN Clinical Practice Guidelines in Oncology for Survivorship v.2.2025; ImpediMed Q4 FY26 Investor Presentation; ImpediMed/ASBrS 2026 clinical showcase. Detects subclinical lymphoedema before visible symptoms appear, supporting earlier intervention Tracks muscle mass and hydration to guide exercise, nutrition, and recovery planning Extends naturally into multidisciplinary programs — wellness, lifestyle medicine, and exercise oncology Operates on the same cloud platform as SOZO, enabling seamless trending as patients move across care settings CANCER SURVIVORSHIP Heart failure affects an estimated 6.7 million people in the United States, with roughly 1 million new diagnoses every year and an outpatient monitoring market ImpediMed estimates at US$600 million. Fluid overload is one of the most common — and most preventable — drivers of hospital readmission in this population, yet clinicians have historically lacked a fast, objective way to monitor it between visits. SOZO Pro is the only FDA-cleared BIS solution for assessing fluid status in heart failure patients and in patients with pacemakers and cardiac implants, using the same HF-Dex® analysis available across the SOZO platform. Medicare coverage now extends to approximately 75% of heart failure patients, and reimbursement continues to expand alongside the platform's broader coverage gains. Having established SOZO Pro's regulatory foundation in cardiac care, ImpediMed's near-term priority is disciplined commercial execution: expanding the sales effort in states with the strongest existing reimbursement, while supporting investigator-initiated trials that build the clinical evidence base needed to broaden indication language and payer coverage further. HEART HEALTH MANAGEMENT 07 Source: ImpediMed Q4 FY26 Quarterly Activities Report and Investor Presentation (ASX: IPD). Extending SOZO® Pro into Cardiac Care 6.7M U.S. heart failure patients $600M Estimated U.S. outpatient HF monitoring market ~1M New heart failure diagnoses annually ~75% HF patients now covered by Medicare for SOZO The rapid rise of GLP-1 medications has made weight management one of the fastest-growing areas in medicine — and exposed a gap in how progress is measured. Rapid weight loss with GLP-1s or other therapies can affect weight loss by up to 20%. Weight alone cannot distinguish fat loss from the muscle loss that so often accompanies rapid weight reduction, and clinical guidelines are increasingly calling for body composition surveillance that goes beyond the scale. SOZO addresses this gap directly. With SOZO Pro's integrated weight measurement layered onto BodyComp™ Analysis, clinicians can track fat mass, muscle mass, and hydration status throughout a patient's weight-loss journey, helping preserve lean mass and personalise care as GLP-1 adoption continues to accelerate. Within the past 12 months, there has been rapid expansion of clinical guidelines from leading societies supporting surveillance of body composition in medical weight management: FY26 saw growing momentum in this segment, as medical weight management is touching all patient populations, building natural synergies across cancer survivorship and cardiology customer relationships. 08 Beyond the Scale in the GLP-1 Era MEDICAL WEIGHT MANAGEMENT The Lancet Diabetes & Endocrinology Commission1 • Traditional measures of obesity, such as BMI, should only be used as a surrogate measure of health risk at a population level. • Clinical Assessment of Obesity requires confirmation by objective measurements, which can include direct body fat measurement by bioimpedance. • Baseline and serial assessment of lean body mass during weight loss pharmacotherapy. • Use of validated tools—such as bioimpedance—to monitor changes in fat mass and lean mass. • Standard 6.4 Obesity Medicine Data Collection: Required Variables states that accredited programs must capture patient variables for data collection and outcomes monitoring for obesity medicine patients, which includes body fat percentage at initial presentation and change over time. The Obesity Society, in collaboration with the Obesity Medicine Association, American Society for Nutrition (ASN), and American College of Lifestyle Medicine (ACLM)2 The American College of Surgeons Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP® )3 1. Rubino, Francesco et al. Definition and diagnostic criteria of clinical obesity. The Lancet Diabetes & Endocrinology, Volume 13, Issue 3, 221 – 26 2. Mozzafarian et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. The American Journal of Clinical Nutrition Volume 122, Issue 1, July 2025, Pages 344-36 3. Optimal Resources for Metabolic and Bariatric Surgery. American College of Surgeons, 2022 One system. One cloud-based platform. One continuous patient record. Delivering Personalised Care. Across all three segments, the underlying platform is the same: one non-invasive, 30-second scan; one FDA-cleared, CE-marked, and ARTG-listed device; and one secure cloud record that follows the patient across their care journey. It is this combination — proven technology, expanding clinical guideline support, and a widening base of reimbursed, high-value use cases — that positions the SOZO Digital Health Platform for continued growth in FY27 and beyond. 09 Actionable Aggregates and trends patient data for actionable insights Quick 30-second, non-invasive test Secure Controlled access to the HITRUST certified SOZO network with unique security settings Scalable Patient data accessible by care teams across the health system Continued momentum with private payors Since June 2023, ImpediMed has secured coverage for over 331 million lives in the U.S., including nine of the top ten private payors and several regional payors. During the year the number of states with coverage above 90% increased from 36 to 47 and of these 38 states have coverage above 95%. Technology adoption – increased patient testing Since the launch of SOZO, over 1.5 million patient tests have been conducted, with 324,000 in FY26, representing a 13% year-over-year increase. Q4 FY26 saw a record 87,000 tests, an 18% increase compared with the same quarter of the previous year. This patient database, which has grown at a 3-year CAGR of 16%, has enhanced the accuracy of SOZO, automated key protocols, improved algorithms, and provided real-world data for regulatory clearances. FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 Operating and Financial Review 10 Thousands 50 100 150 200 250 300 350 0 FY26 1. Compound Annual Growth Rate (based on annual totals) 16% 3-year CAGR1 SOZO Patient Tests (000s) New Measurement Follow-up Measurement Installed base growth Global installed base grew 9% over the year finishing FY26 with 1,236 SOZO systems installed. In the U.S., installed base grew in FY26 by 59 units or 10% to 642 units. In FY26 a total of 111 new units were installed, down 3% compared with 114 new units installed in FY25. In Q4 FY26 a total of 36 new units were placed in the U.S., an increase of 20% compared with the previous quarter, demonstrating improved momentum resulting from the emerging impact of the focus on sales and marketing execution. In the Rest of World (ROW) markets, the installed base grew 7% to 594 units, a net increase of 38 units over FY25. The majority of ROW sales were made in Australia via the Company’s distribution partner. Opening IB1 New devices added 1. Net of churn in current half Operating and Financial Review Installed Base Units 1H FY25 2H FY25 1H FY26 2H FY26 1H FY25 2H FY25 1H FY26 2H FY26 1H FY25 2H FY25 1H FY26 2H FY26 1,197 1,236 102 76 1,065 1,139 77 80 642 66 523 583 48 66 599 45 594 10 542 556 29 14 598 57 11 Up 9% vs FY25 Up 7% vs FY25 Up 10% vs FY25 GLOBAL U.S. REST OF WORLD Global revenue Total revenue in FY26 was $14.6 million, an increase of 15% or $1.9 million compared with FY25. In constant currency1 total revenue was $15.3 million, up 20% compared with the previous year. The increase in revenue was mainly due to new SOZO system sales and recurring revenue growth in the North America market. Significantly, revenue associated with SOZO Core Business2 in FY26 was $14.1 million, up $2.0 million or 17% compared with FY25. Revenue in North America was $13.3 million, an increase of $1.7 million or 15% compared with FY25. SOZO Core Business Annual Recurring Revenue (ARR) on contracts was $14.4 million at 30 June 2026, compared with $14.0 million at 30 June 2025. Churn rate 6.8%4 . In constant currency, ARR was $15.8 million at 30 June 2026. SOZO Core Business Total Contract Value (TCV)5 signed in FY26 was $19.5 million, compared with $19.2 million signed in FY25. In constant currency, FY26 TCV was $20.6 million. 1.Constant currency removes the impact of foreign exchange rate movements to facilitate comparability of operational performance. This is done by converting the current year revenue of entities that use currencies other than Australian dollars at the average rates that were applicable in the prior year. The constant currency amounts have been calculated by translating US dollar values to Australian dollars using the average exchange rate for FY25 (0.6459). 2.SOZO Core Business represents revenue from SOZO contracts in the Oncology/Lymphoedema market and excludes SOZO Clinical Business and legacy device/other revenues. 3.Annual Recurring Revenue (ARR) represents the amount of revenue reasonably expected to be recognised for the next 12-month period based on existing contracts, assuming installation upon sale and no churn. The exchange rate used for 2H FY26 ARR calculation was 0.7098 (2H FY25: 0.6434). 4.Based on SOZO units globally. [Number of units cancelled or not renewed in the period] / [Average cumulative unit placements in the period]. 5.SOZO Core Business Total Contracted Value (TCV) includes any consideration for the sale of SOZO units as well as the total licence fees for the duration of the signed contracts. Typically, these contracts are for a period of three years. Legacy/other SOZO Reported Constant Currency Reported Constant Currency Unallocated ROW North America $A millions $A millions $A millions $A millions Operating and Financial Review FY24 FY25 FY26 10.3 0.1 0.1 9.6 12.2 10.3 12.7 9.3 11.5 0.9 1.1 14.6 13.3 1.3 FY24 FY25 FY26 1H FY26 2H FY26 14.8 15.8 1H FY25 2H FY25 12.5 14.0 1H FY25 2H FY25 1H FY26 2H FY26 8.2 11.1 8.9 11.7 Global Revenue by Category Global Revenue by Geography SOZO Core Business ARR SOZO Core Business TCV 0.7 0.5 12.7 14.2 0.4 14.6 12 12.5 8.0 11.3 8.7 10.7 14.0 14.4 14.4 $15.3m in constant currency $15.3m in constant currency Other financial results Operating and Financial Review Gross margin Gross profit margin was 87% for the year, compared with 86% in FY25. Finance and other income Net finance expense for the year was $3.6 million, an increase of $3.4 million compared with FY25 driven by a full year of interest expense associated with the SWK credit agreement executed in FY25. Total other income for the year was $1.2 million, in line with FY25. Operating expenses Total operating expenses for the year were $35.2 million, even with FY25 operating expenses of $35.2 million. Salaries and benefits in FY26 were $19.6 million, a decrease of $0.4 million compared with the salaries and benefits expense in FY25 of $20.0 million. Share-based payments were $0.8 million, $0.8 million lower compared with the $1.6 million in FY25. Together salaries and benefits and share-based payments represent 58% of total operating expenses (FY25: 61%). Administration expenses were $3.0 million for the year, a decrease of $0.2 million compared with FY25. Depreciation and amortisation expenses were $4.2 million, a decrease of $0.4 million compared with FY25. Operating result Net loss from operations was $24.9 million in FY26, compared with $23.2 million in FY25. The increased loss was driven by higher net finance expense, partially offset by higher gross profit resulting from new SOZO system sales and recurring revenue growth, lower salaries and benefits and share-based payments expense, and lower depreciation and amortization. Cash Cash and cash equivalents were $15.3 million at 30 June 2026 compared with $22.2 million at 30 June 2025. Net cash used in operating activities during FY26 was $17.9 million compared with $15.6 million in the prior year. The net cash used in operating activities in the period includes receipts from government grants/tax incentives of $1.2 million compared with $0.9 million in FY25. Net cash used in investing activities during FY26 was $0.6 million compared with zero in FY25. 13 1. Including Executive Directors 2. Excluding Non-executive Directors Employee Category 2026 Male % Total % Female Male % Total % Female 2025 Non-executive Directors Executive team1 Company-wide2 3 5 37 75% 50% 56% 1 5 29 25% 50% 44% 4 10 66 3 4 37 75% 40% 48% 1 6 40 25% 60% 52% 4 10 77 CEO Statement Commitment to Patient Outcomes, Sustainability, and Good Governance FY2026 impact and ESG update At ImpediMed, our mission is to improve patient outcomes by setting new standards of care in fluid and body composition management. In FY26, this mission continued to guide our commitment to clinical excellence, compliance, sustainability, social responsibility, and strong governance, especially as the Company extends its reach into Heart Health and Weight Management alongside its core work in Cancer Survivorship. Caring for our Patients Since SOZO’s launch, more than 1.5 million patient tests have now been completed globally, with 324,000 of those conducted in FY26 alone, a 13% increase year-over-year. As SOZO becomes embedded across a broader range of care pathways, its ability to transform clinical outcomes and improve lives continues to grow. Caring for our Planet We continue to minimise our environmental footprint through sustainable practices, including reducing waste, optimising energy usage, and ensuring responsible sourcing of materials. We work with our contract manufacturers and largest suppliers to uphold these standards, and understand and minimise our environmental impact through device recycling programs, with end-of-life equipment and parts disposed of through certified methods. Caring for our People Diversity is a cornerstone of our strength and a driver of innovation. ImpediMed’s Board and Executive Leadership team reflect a broad range of skills, backgrounds and experiences that enable us to better serve the global healthcare community. The table below summarises the number of women and men across the organisation as at 30 June. Environmental, Social and Governance 14 Erik Anderson Managing Director and CEO Environmental, Social and Governance We also uphold our social responsibilities to employees, customers, and communities, including local volunteering programs and employee volunteer days, and continued participation in U.S. Cancer Survivorship communities and forums. Strong governance and Board evolution Each year ImpediMed describes its corporate governance framework and its adherence to the ASX Corporate Governance Principles and Recommendations (4th Edition), in its Corporate Governance Statement, which is available in the Investor section on ImpediMed’s website. The current Board was established in September 2023, bringing renewed focus on governance, accountability and commercial oversight, and incl